treatment

Women With AML Have Worse Outcomes With Gemtuzumab Ozogamicin

Original Publication Date
Article Source
External Web Content
Combination gemtuzumab ozogamicin (GO) and cytarabine is no more effective than standard chemotherapy for older adults with previously untreated, standard-risk acute myeloid leukemia (AML), a phase 2/3 trial suggests. In fact, GO plus cytarabine was associated with worse event…

Aspaveli® (pegcetacoplan) approved in EU as orphan drug for treatment of PNH

Original Publication Date
Article Source
External Web Content
Published: Dec 15, 2021 STOCKHOLM, Dec. 15, 2021 /PRNewswire/ -- The first targeted C3 therapy approved in the EU Approval based on results from head-to-head PEGASUS phase 3 study where Aspaveli demonstrated superiority to eculizumab in improving haemoglobin levels1 Aspaveli will…

Andrew Brunner

Institution
Harvard Medical School
Physician Status
accepting new patients
Primary Disease Area of Focus
Myelodysplastic Syndromes (MDS)
About
Dr. Andrew Brunner is an Assistant Professor, Medicine at Harvard Medical School and Assistant in Medicine at the Center for Leukemia at Massachusetts General Hospital in Boston, Massachusetts. His research is focused toward understanding treatment patterns and patient outcomes in MDS and other advanced hematologic malignancies, and to develop new treatments for these patients. He is involved in clinical trials for all stages of MDS with an overall goal of tailoring treatment to improve the outcomes of these patients.

ASTEX PHARMACEUTICALS PRESENTS OVERALL SURVIVAL DATA FROM ASCERTAIN PHASE 3 STUDY OF ORAL HYPOMETHYLATING AGENT INQOVI® (DECITABINE AND CEDAZURIDINE) IN MDS AND CMML AT INTERNATIONAL CONGRESS ON MYELODYSPLASTIC SYNDROMES

Original Publication Date
Article Source
External Web Content
Study achieved median overall survival of 31.7 months Updated efficacy data demonstrated an overall response rate of 62%, with 22% of patients achieving a complete response INQOVI is the only oral hypomethylating agent with equivalent exposure to its intravenous (IV) form…
Subscribe to treatment

Website Feedback

Please use this feedback form to report website issues only. For other issues concerning patients and families, please email help@aamds.org or use the Patient and Family Helpline here.